UTHR - Earnings call transcript Q4 2018 | United Therapeutics Corporation

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to United Therapeutics Corporation Fourth Quarter and Full Year 2018 Earnings Call. My name is Nicole, and I'll be your conference operator today. [Operator Instructions] I will now to turn the conference over to James Edgemond, Chief Financial Officer of United Therapeutics.

James Edgemond

Thank you. Good morning. to and to call. full pleasure Corporation United my quarter fourth year is welcome the you Therapeutics It XXXX earnings me are call on Accompanying Dr. today's Officer; Martine Chief Chairman Rothblatt, Executive our and Mr. Operating our Benkowitz, President Chief Michael Officer. and And call, earnings in to Dr. addition, to are welcome we this pleased and Rochester for Professor Pulmonary Medical Orenitram. a committee Medicine, member Center FREEDOM-EV Division of at study Medicine White, and Physiology and Care Jim the the the of in Pharmacology of Critical University of steering Dr. question-and-answer portion questions the the will earnings the answer during White be to of regarding FREEDOM-EV call available study. from data Remarks or today events. will include regarding forward-looking statements, representing our beliefs expectations future These statements risks uncertainties materially. actual that may involve to differ results and cause

our our and www.unither.com. These solely the may as and to results Today's remarks clinical or and are investors other with SEC on Generally also prepared information respect on or to GAAP update that directly Accounting Accepted usage. serve available obligation Full suggest Principles. remarks the with will Reconciliations latest measures to basis Our are safe trials most educate not for risks intended unapproved include intended our financial XX-K release accordance were can progress developments statements. in assume not of including non-GAAP that products for medical the contain on comparable measures remarks website Today's found is discuss at earnings financial for in products. investigational any to to US financial and no to and prescribing forward-looking of additional measures our decision-making may XX-Q any products effective are and filings be the available website. Form these uncertainties. information We

be call sections. two this morning divided into Our earnings will

XXXX an of and results Dr. quarter and During financial then Therapeutics and this overview the and year business full earnings Benkowitz provide transition results financial myself full portion fourth call, the and question the activities of Mr. year Rothblatt, business United activity. fourth first and and of quarter teleconference of on will for Rothblatt, will Dr. our XXXX answer to we the section

transition then question White Mr. FREEDOM-EV the to this section answer of then to Dr. teleconference the call portion will will the We second for clinical of Benkowitz and and to study introduce transition I and the and Dr. discuss earnings myself. White,

I the an Rothblatt and of over full year fourth of financial and turn Now will results call to for Dr. quarter overview United business XXXX the activities Therapeutics.

Martine Rothblatt

you, to conference Thank annual And fourth results our James. quarter Welcome call. everybody. good and morning XXXX

X.XX X:XX, James Edgemond, financial James agenda that Financial to As the indicated, call our Benkowitz, the activities Officer. joining Chief and our I'll results be and review for our review and be from business President for will this Mike will me

who James FREEDOM-EV Dr. implications and introduce Edgemind review James supported to by and I few Benkowitz Michael - will study to be this going who James. and X:XX, will introductory led Jim myself, complete United for by Edgemond White half I'm that White the its Jim and Mike call During Jim Therapeutics. At first either hour have over answers directed chairmanship remarks, can turn and to the questions after the we'll or White of

a record trial, year including hypertension toward XXXX agreements honored and very acquire committee major field for X including to steering transformative our deal and for representing Phase to He was are treated existing the top Ralinepag, for with significant member to BEAT opinion readouts new of FREEDOM-EV therapy. successful our of and near date. leaders a time, studies progress continue key At an the of White our this FREEDOM-EV number the we signed patients clincial on candidates, with We United in-licensing DISTINCT same four truly pulmonary for commercial one in is our We to call. of goals, product have our Therapeutics. of Dr. execute largest tier agreement arterial against the an to clinical being a has readout study. us the increase been and treprostinil term

Let go to the now me numbers.

to million reflecting in $XXX grew in in declined to million quarter fourth of quarter profits from share with $XXX loss compared exclusivity, XXXX revenues a $XX share, per our million fourth of at quarter in Our XXXX. 'XX fourth We XXXX from the 'XX, $X.XX but income per million ended Adcirca calendar-year end $XX only diluted diluted quarter the 'XX. with of net $XX.XX fourth

Let pipeline. me now clinical late-stage our review

study analogue is would expect earlier, of our BEAT period a is our esuberaprost, we mentioned product. and are prostacyclin Phase Tyvaso potent significantly lengthen Tyvaso. in patients studies X of oral study time successful our year. with It taken able this the the called to As to if the unblind DISTINCT morbidity-mortality BEAT use and combination

lung that have expect between for a from for patients monoclonal the cancer. its to should with is we note, DISTINCT year. cases. product own study grow and Phase our that dinutuximab We and XX,XXX this of ready our cell antibody dinutuximab Tyvaso could Jude Of that to in-licensed humanized is it form X,XXX next regard St. of small X testing

of expect thousands two addition four enroll many we within for advance open that next patients also they have new these XX in we of United which near-term would other to up point enrollment trials in them months. the readouts, that Therapeutics. the to Now Phase Each to X we willfully

approved first context of called pulmonary very GROUP is of The there called disease these of this form pulmonary pulmonary lung a INCREASE, X and test be of hypertension which hypertension interstitial hypertension the a the is first in therapy. is for of will which

two called therapy which of large hypertension in is this with too Group in occurring of testing be specifically X X study, segment pulmonary hypertension. It PERFECT is for suffering Group the Several is very from pulmonary patients patients occurs first with tens would hypertension. pulmonary the thousands available COPD, this and study COPD. of nicely that COPD enrolling, Study X and patients second the also The Phase

is to oral that single and agent functionality is there chemical failure by World and a in once of that Again a and Group cells our of pathway progression pulmonary place on patients the of of their a is the three Fraction. those a as for Organization hypertension. now Patients an heart the would even natural called is hypertension be therapy. infusion in office Preserved trial, going bit This have able now autologous undertaking improves longer. that approved for cells' Ejection months bio right into own which transfected Orenitram gene third Phase with perhaps not gene doctor's little the take, go history been we're would Phase turn And drug-resistant answers, to We study mention help into combat called is several two questions hypertension. right The I'd X pulmonary a our with in an orphan a pulmonary systems. also the developments medicine treatment them hypertension it called is microscopic which drug area cells trial these it X own Well, for pulmonary factory which trial pulmonary is like relating delivery X wide-open SOUTHPAW designs. to basically, before to SAPPHIRE, Health and that therapy to every I fourth hypertension, the patient's over this turn

the of for augment hundreds find with intravenous by we that Medtronic number Remodulin Remodulin. can First, many patients commercial system from that implantable the agreement the for benefit will

patients of expanded Second, options and RemUnity submit to subcutaneous provide Trevyent on approvals two we are for preparing to Remodulin. regulatory

of the mentioned propel range cumulative to Tyvaso XX,XXX three and Taken addition previously. together, should mentioned these - in to devices the range X,XXX for range

MDI Next, we liquid from called Spiriva forms of a dry MannKind and Medscape. system brand a are powder advancing also two new delivery; Tyvaso drug from

for you Therapeutics. these United can from year results, of transformative As see been a all it's

and for any of longer to of kindly have the to the life us, Benkowitz of X remarks a We like more all unblinding in to of these activity in and different for Phase trials never With now And our trials and patients. new open areas the for going hopefully, and the the with therapy. ask phones efficacy for duration I'd our met make all operator both in questions covered patients to the the introductory activity our Mike treprostinil clinical drug related all more to behind beneficial and technologies with our I Edgemond. on up to the of terms delivery this the James myself, had of clinic agents

questions and open you time Freedom-EV you study, X.XX, the get the until hold at Dr. to lines of you any the queue readout. can questions. you can for relating those benefit that please the have hearing Freedom-EV If freshly up the review have Operator, back of expert in White's

Operator

Gould first our from And Instructions] question Carter UBS. from comes [Operator

Your line is open. now

Unidentified Analyst

anticipate you Hi, impact taking in how you for in three evolve years? that payer your [inaudible] pipeline expect our Maybe talk and look we you're assets. about thinking about should new evolving what way, will purchase Carter. another five purchases launches with for the questions. might how PAH do and attitude in Thanks payer like PAH space next to Could put the payer

Martine Rothblatt

question, interesting for really it. So thanks asking

I person the perhaps oversees you out think who your And Company perspective payers that Mike on qualified individuals, regular President. to our of probably the strategic operations basis with question He would in if all our payer most our talented be evolving the very interface provide Benkowitz, individuals Mike, could answer the group. a called landscape.

Michael Benkowitz

of reining evolves. energy at is federal now There those are I cost and prescription Yeah, we to the yeah, and of eye lot interesting different be to drug about proposals question, bandied certainly government keeping what on. I on so an Martine. being, our it prices an seems a about approach the think is in concern I eventually of that certainly of lot and a eye an keep lot Thanks think and level certainly one a a See considered things. guess right

are think as proposals happen what's different so said, that going are, hard being I bandied this because there to exactly at predict about. I to many point and approaches it's

as a we mindful to as to we to think but of Remodulin. years. it Last price we've expense have think year, in I done a those and time so and and medicines sure I historically, that increases. also That of the being certainly the was for we're approach have price think I we in relates really took therapies first make responsibility been when modest PAH, eight of that we've therapies, cost our increase our

our typically drug digits and we that we we think Our other to prices low affordable. sure are single to make keep to just drugs we increases responsibility a have price mid respect -- with

We our things a number of afford other drugs. to assist that patients also do can't

offer We to help cards the of certainly program. with while we'll them that things the to for an we keep a paying to think a and for once the respond to competitive appropriate is government and community. bill so obligation financial this patient lot have a their generous attention co-pay I assistance a patients very We is quarterly are react to to, think or proposal and -- do continuing and on there eye that PAH we're right

Operator

next comes Hartaj Oppenheimer question Company. from from & Singh Our

Your line open. now is

Hartaj Singh

that's I and going year, we a disease treat question took release how just cell know, color in later patients sort and had a guess half could you're How see pretty there you. to around us expect have do recruitment on to is, lung press to at close readouts a to big study. a a it's -- Thank you look and have it to question endpoints. recruited just I recruit is this like you the that XXX and know give small the the some to my I then disease, study just primary year secondary what patients, looking like? you're you Could looked about of cancer. a the readout would tough dinutuximab. the

Martine Rothblatt

for lung much cell small are question. of really of cancer. or a the three Absolutely, expert scientific us none so medical the on Thanks specifically

to Precision it answer that The worldwide network be I'll So enrolled a provide our kind Oncology oncology an and have level study XX,XXX-foot a centers. the partner of will called with they was of, CRO as tremendous question.

study although felt study, large relatively us, been we the Oncology So that. work it on enrolled we've a quickly. for it with And Precision very pleased was

most for we into analytic And in lung on they dinutuximab promising of green the what approval did the next markers cancer. an existing dashboard would for of its and number small-cell have neuroblastoma. Before went small strongly for the that of based target in-vitro Oncology terms cell, was exhaustive go in very analysis basically, Precision after be terms

felt we map The about favor. strong and doing was its So that. optimistic in heat

the into launched we So study.

relatively all enrolled DMSP a passed we've fact is positive I the think that do type sign. I gateway. believe of of the it rapidly

and ahead hopefully, and mentioned agents be unblinding I mAb. a still kinetic introductory only the remarks would So we of half, now the dinutuximab in timing for as a humanized that waiting want we're the testing optimistic part of second in-licensed enough current and that that which in we this went thing is for I the my as were of half earlier the second this that believe year, form

So us expand to with attractive reduce kinetic for really with can now lung comparability including is market form up study Also associated hopeful kinetic form target market. the effective currently option the allow working And a antibody. targeting third Precision profile and attractive humanized I'm GDX the cancer third is be multi-form. from the have neuroblastoma larger in more also we'll side of that course, this the this glioblastoma effect also to for us. to but most looking we're small-cell target, the a and even both And line which humanized the to do

are So Hartaj. in a platform we lot investing this

should Thanks new you much can facility end operation manufacturing year additional drug we'll hopefully, and trial on go Odessa It product -- dinutuximab could As I next as trial next the this form. into also it queue move cell and would end up neuroblastoma, operator, of hopefully, into can year, well. at for up should TDM so of go the for have for mentioned, a if focus comparability the for humanized we question. before minimum, the that an and we into be for a by super the we've exciting study small built the

Operator

Sachs. Our next from question Wang comes from Terence Goldman

Your is line open. now

Unidentified Analyst

impact the prescribing on trends Jason it's Freedom-EV side, seen the less you patient Freedom-EV on had is clinical more side, question any have initial Terence, the mix from This or following but from quick a readout? for Company

Martine Rothblatt

presenter ask hear the question he Dr. queue because have that of with just you will Jason. get and Pulmonary Conference expert to Institute question, going Orenitram that after last Research disease tier top more White's much to a in the Thanks answer I'm back the intersects you review was a to month. you Vascular at intelligent

to queue, So your if confident Operator, I'm just able half pick be question you would in we'll kindly back hour. get next question. in next up

Operator

comes next Our Securities. Moussatos Liana from Wedbush question from

now. You're

now is Your open. line

Liana Moussatos

readouts in positive and would any clinical are or you need BEAT with isn't steps it's there Tyvaso, in it's you extra After tested combination an being assuming approved regulatory before because submit NDA? Esuberaprost

Martine Rothblatt

terms of the the portion, great a the have the the of team question filing on CMC and answer and we Yes, no, portion. it's Liana that's clinical really is portion a awesome because been the working like medical clinical in [inaudible]

Phase that everything could we that actually has study. get possible for submitted our So done in so time filing been record X Company after a

like time example, six NDA For is of submit study a to industry, like the in unblinded. typical period months is the an kind after

complex is already it's we NDA. know is drug a do just to the for we you a a isomer drug the the ischemic molecule single moment Japan thing employed, beginning had no single that parts -- on We NDA in effective as able the approved. then but other mentioned manufacture together drug, it greatest that ourselves. studies, additional was very we're stability the world the and a And single that otherwise using, companies we and isomer, even months that beraprost. drug there many on which Esuberaprost in just we'll and period of as that And a during were to our put great the are not the together a are it about able and get chemical an that's that's to anything that's partners B the of very, would isomer no three form manufactured drug one hop aiming Esuberaprost three-month of are ago, additional a The we're than exciting putting because trial manufacturing

commercial to drug of then all is And the that So XXXX. fourth let's is this that hold lead would that toes there that year. the that say Liana, of year NDA second and get have at this we unblind say us could fingers of in quarter a crossing the our this no we would hope up quarter and let's FDA that of before in filed launch

who that ever Now, Therapeutics me, undergo thing lots is taking fatal unfortunately, and can always interesting our at and cetera. Whites of But be the agent because which of tricky most time as in and patient will complex dose, the cetera, already it's and industry like being Tyvaso. using et know BEAT saints thinking Doctor with about generally the patients at you patients one there which I actually about and launch United drugs if Esuberaprost, algorithms exactly of give of care mentioned for what always is we're exciting a et sticking with to condition patient Tyvaso on is which the already top we the of lots the it's approved a am tested as you what are

be reduces has to kind believe of can Tyvaso are and no you the it's like I that your and adding morbidity So Tyvaso to on first hockey this that prove because Esuberaprost immediate that drug if we Then mortality. could what I brainer. an stick call if takeup like a

you're question you if got what stick am hoping is uptake Operator, on them like a for. I hockey add please. Tyvaso, get on to Esuberaprost, and patient like So next you that's

Operator

next Martin Credit question from from Our Ulster Suisse. comes

now open. is line Your

Martin Ulster

PVR of selexipag to Arena studies your including had addition prior head about Pharma talked pivotal licensing to Martine, Ralinepag study an look of Ralinepag, to changes. the to head hemodynamic three at versus

that's evaluating and might Just thinking so trial curious available? path about data be a those if Thanks. clinical if you're when still

Martine Rothblatt

question. insightful really a that's Yes,

or her do. very time agreement Ralinepag good come by with when Ralinepag And by study we the three to In way, we Golden, So on Medical successfully Peterson, about of had the Gil we've approved that the they'll Dr. will the the clinical is meantime, different she trial three clinical as now consensus Dr. Arena whether Officer, to the all seven enrolling. ways Phase that to be a of together with of Chief trials. to what possibilities would a in-licensed different individual the attractive she that, analyze X those from team of the get found like Lee and on just all out our our reached who's in FDA trials development and team and to charge head-to-head began FDA

with involved So we so patients actual on. - and

three smaller and only can of definitely on FDA, of path approval the on with data study, I is morbidity-mortality, say that's heat Phase significant X previous will, highly think Number I studies all Company focused factor two, different result get on to an map statistically, of study drug doing So need three so know these X that priority. much you you a based one out and good seven seven if outcomes and Arena's an a highly exercise studies, are really or executing whether is patients, and these study a that's get get and ways accomplishment to the outcome very just ways our our the that's significant you study approval, to clear their through being which we on approval committed depending secondary and those results statistically statistically the to getting out having different told studies, and

had studies uniquely to daily compared twice and instead selexipag that the Ralinepag, teams X just of Phase terms over as markets as the studies enticing the Already. know some once of the to important However, to I their with United position Therapeutics. that chair of beyond three our exciting We've market very prescriptions any the Peterson is attractive to the additional to ability more and trials. and extremely also it's Operator, undertake just at Right and head-to-head what data but Dr. want had never Golden to more undertake features daily I decide reiterate product. you it we Ralinepag very and of of will James baton there prepare of bat and dosing of will in as the call that in Arena leave additional in you an us the Dr. pipeline. of the first off we Treprostinil take then for shows to drugs Ralinepag, the half second We've conclude let half the soon the hand to White, course, dynamics. time to selexipag was call all for never Dr. in

time drugs White. patients Dr. our delivery of Operator, of I just the believe now and can opportunities technology, I he'll for call and uniqueness it's going mean, hypertension. and Dr. renaissance Dr. kind Edgemond, our So Edgemond and of the awesome of a White. the super drug the all be treatment turn to over James pulmonary you introduce to chairmanship novelty with

James Edgemond

Martine. you, Thank

provide on to this initial on to setting. teleconference morning's White Freedom-EV questions Mr. White the earnings we some join are pleased this we will Dr. opening teleconference. thoughts Dr. clinical transition take second And the completes clinical White? Let's of after and morning section Dr. Freedom-EV study White, and his have our and to insights Benkowitz myself remarks, Dr. for

Jim White

think Good long everybody. making Barcelona. what share take I an made in at that exciting have in people that I the to we dataset get is my a to was gotten trust look the already privilege really It's a time presentation to some extremely and morning,

by of and I driven across clinical disease think probably decreased by overall think a data is clinical progression. importantly risk of taking XX% most demonstrated, score key I clinical that boarding And to NT-proBNP As package was part Orenitram like also, walk. including the XX% class, physicians see, impressive. patients worsening improved improvement study after versus of It measures this really the that in care status and our functional WHO Freedom-EV placebo the the the reduction

the and using very that also of data and initially very were Orenitram are likely they're I part mortality drug alive similar to are close that of assessment package. clinicians Our assigned is placebo that study with to profile address second only of design week disease study just managing. I to frequent and at more -- intriguing XX% wanted comfortable to very study visits Freedom-EV progression at end XX that with point in mandatory and Remodulin, than side for and so those person X safety that the Orenitram a be on in calls comfortable this the indicated mandatory a X, involved, weekly who of reduction attentive closure person were visits the is vital status profile they a effect randomized and calls weekly phone phone think team. effects the in contact the was the the likely because the the these extensive. tolerability those very But phone adverse investigator with not

So encouraged the to effect drug up adverse to the participants do be managing profile. be could helped titration and

think disease probably symptoms death. serious I of this the contact hospitalization to degree a or high brought progression before like forefront event more

FREEDOM-EV some was sensible. in XXXX, possible a study the want combination what paradigm of fact and FREEDOM-EV to prescribers different that clinical All wasn't disease as a hospitalization in to At on be the would less combination likely earliest right just practice time patients very to time the would strategy. clinical at we in coming be attention pulmonary up were time remind hospitalizations launched when simply think I event less as practice clinical worsening of much clinic calling and there end Because the more detail routine and therapy frequent that eventually. progression study contact, people only followed pursue in very to or I the background in so the exclusively, was sequential this intervention hypertension. study everyday the in would mine trying likely design,

FREEDOM-EV monotherapy time very six of months be point after months fact at revaluation indicated the protocol a a three a a time to someone on Orenitram monotherapy first point, to design XX-day physician was first or study without drug. So a the add added therapy our in re-evaluating on would early to push so the envelope instead

clinically functional therapy the was The the for the the a first time of since topline meters disease demographics and was data clinical combination median this of positively similar was log-rank actually occurred they the ended XXX time envelope predominantly The therapy. other unadjusted to already event class was that not separation similar is other tremendous XX event the studies. clinical and group group the weeks clinical that's participant’s What the studies X.XXX. about at So a a early driven trial for very clinical a early improvements a of and I'm a frequent strain remarkable up early symptoms in at increasingly months significant by reduced made marker six this and right diagnosis standard. in had as really important. II tolerance very NT-proBNP improvements, driven – very young and worsening A statistically parts being us BNP well recognized analysis meeting relevant XX is package of were EV exercise that of age that of [inaudible]. excited. XX% levels significantly with to prognosticly that was data heart almost two The pushing is There responses

baseline was less symptomatic NT-proBNP because and a were surprising, people's longer actually with is were levels Class II functional and at little in walks. high this the quite first participants mostly The mostly

our excited of heart to We're probably in out week the also class experts just to nice the and very improved clinician And it the the especially be degree of oral emerging continued in like us to heart in fully the important fact from reductions want and the Oral presumably the reductions multimodal board durable. on me. was baseline XX that XX most separate at reflector improvements functional outcome looking BNP not quite angles treprostinil elevated to of about important multiple and groups that patient So these of And the fact non-obese at risk after NT-proBNP and a function. highlighted reflect board really reemphasize breathless really of which going risk cares for walking the functional score, just facilitated for separated for that that importance assessment, critical population week NT-proBNP both the WHO very it’s marked large suggesting placebo factor our reduction is this less was the the not NT-proBNP we curves risk the I reported treprostinil agree class treating we just walk. important in the that very observed, strain right right FDA it’s treprostinil saw is a about. at

WHO we factors treprostinil did factors. that endpoint that have unfavorable for And statistical what higher much study participants important So was and likely out I substantially certainly board plan. class. not and frankly that started that the and it's in have the advocated mark is risk patients their the of even has That to to impacted point new occurred This the underwater a risk score not were when that And in that to able something a to improved started results important favorable drug score many the oral survival want fear of of is the treprostinil were pre-specified this we're risk want approval noninvasive clinical unblind comparison data to participants since this participants patients risk that predictor prognosticly definitely simplified the And to the that curve biggest improvement by placebo. at the likely French treprostinil expect achieve patients. Adempas adjusted The say symptoms. baseline, that too both most ball there is really drugs and fact to were the that the which the when that analysis then oral we placebo in to see is oral functional deaths. assigned the Orenitram we at worse. primary least extremes we and the worsening

much separate XX% propensity sort of more, X.XXXX. can the score recently this drops And hazard two these a groups with are reduction the studies. so and numbers is the more to P You other of a adjusted value events adjusted goes X.XX in of ratio line risk reported risk substantially think to the

unexpected. very that I've much ambition So was at fact, identical a same analysis ambition using the this similar exact analysis And the of in were baseline. groups and at done the baseline data

compared not XX in became oral versus for sorry The drop highly and results occurred time for that time this versus be the significant. of those to within randomization in with dropouts so declining to is as that placebo. we yet Risk So, achieved as quite of that prostacyclin XX% treprostinils for study number XX and we effective week first drug markedly achieved We The were and outs, improved were the due Unfortunately, to differences underwater the fact of we weeks [inaudible]. significant on same overall and improving saw to apparent majority the at differences at event to it's the XX. to X% week and risk over score I'm as continued those means treprostinil going saw oral everyone the placebo. highly intolerance had participants Assessment a compared the

but overall open we by size volunteered study, the the second in adjust for of the months who a status the reduction that, XXXX most participants portion rank greater in Finally that vital to ago hospitalizations highly significant risk X.XX. mortality treatment, difference left I on and follow-up we initially end label the all to they altogether. had XX% a just stayed vital October, In XX% provide status even during of not patients with after were the events of in adverse initially survival randomized. P Being assigned deaths every size in six participants long-term and balance treprostinil of study on their of decrease once when effect is were discussed oral the XXX the the randomized and most say log the of even mortality the is The substantial study a a benefit initially to suffer risk portion the associated test. effect, that was did X.XX assigned XX%

discussion of the And So I data this I Edgemond. back turn over was to helpful. call the James that hope

James Edgemond

questions Dr. FREEDOM-EV please can study. Nicole, White, the up you open the proceed for Dr study. clinical on freedom teleconference the regarding you offering clinical insight to your thank Great. for for FREEDOM-EV again White

Operator

[Operator JPMorgan. Instructions] from Fye And our question comes from Jessica first

Your line open. is now

Unidentified Analyst

playing Daniel the This taking open Jess. label about medications what mortality Thanks finding? patients Thank our to the is the that do that on into question, how period, for and you for were in went think you. follow-up

Jim White

James. Can I that. answer

James Edgemond

if Yes, question. Dr. you the very you White. please can much answer Dr. question. for thank White, Yes the

Jim White

going the So data you're have really the about. to data, important And analysis. asking that digging stage into the which honestly, started is just XXX now is a this next we be of

about event, another that worsening that initially Orenitram that. we they something of XXX into randomized end - the event, the shows to some parenteral could moved the were going taking placebo had talks dataset Orenitram could they event could what who clinical the from Orenitram when is XXX studies. us actually worsening over prostacyclin. to study. open - moved treatment the happens of assignment a begin patient other placebo they and get be not taking So rich This And had when to Patients continue clinical described driven a is seen label who as over patients that the during initially patients long investigator signed as they sign take very Orenitram

So will data inhales added. to I'm medications discuss delivered process. to what beginning not tell very inhaled allow delivered will into systemically that systemically just excited specifically patients other - we and look another really it But see Orenitram on that dig did we we're be we're prostacyclin sorry, I or can't prostacyclin. either were you I that and to further.

So one on that. for be they to they days up be not could XX beyond could but

deaths we in the than learn we so might think we're information, that their I The Orenitram. their in the number sense. again initial going carefully where that from we things to are have will are that And thing that open assigned can mortality. that when label patients true treprostinil. oral good main will favoring understand explain this very the of to this is have what a shift It the extension there treatment if already randomized happens see we to look better the is to other placebo assignment So most there

right. risk the lot we initially a open you placebo that deaths the time look of there the adjusted XXX to study at about risk placebo At although in again deaths if those So a know adjusted the label more a even the the balanced at closure are time our carries assigned at in October at in data favors or towards - by still And being then recent We're still of the benefit now starts survival the hypothesis finally of deaths to accumulate, not that mortality most course shift initially further the and XXXX a Orenitram are to and deaths, mortality it's favor end benefit. Orenitram. with begins end patients and the way continuing assigned are study to Orenitram.

Operator

Our Thalmann. Matt next from from question comes Ladenburg Catlin

Your is now line open.

James Edgemond

can proceed Nicole question? next the you to

Operator

from And Securities. we Liana Moussatos from question another have Wedbush

now open. is line Your

Liana Moussatos

benefit which data the does of change describing have how Dr. kind Uptravi been that Orenitram, Uptravi you've EV your patients with versus you decision on Orenitram, and the and White might of given you prescribed this would mortality treat this freedom before? with whether Orenitram treated now what

James Edgemond

address thanks Dr. White for the Liana's Yes. question? question. Liana. please you can

Jim White

the think Orenitram I people's that shift going So, perceptions. to are data

a there's think of that. of couple I pieces

FREEDOM-EV drug and lot The this first patients have that is perspective and in. that know Remodulin is doctors like really a think into a I light of new data trust And puts treprostinil of pharmacokinetics, data. and the comes to all that now done the work the the all the blood work, in oral previous in development levels, we've of of development the

about oral drug course be benefits the low associated understand now really avoiding that about not a didn't are an Remodulin, perform dosing, It three that's about Whereas expected, so levels, know are daily a much did form initial people with very, drug likely it's of that and much pharmacokinetics. a all combination very And they in love, to to have just we about look worse which now they why of. confident are at trough the understand I of adverse and this therapies event was times as they the drug profile. before all all more as think people going

that? the versus prescribe you supplement course a show. for do functional going just no that any for the treatment-naive What data. to were whether because the to separate that were of worse. mainly part and whether improve Journal more patients, of that get want carefully present information at day is Patients a specific as study get not data as monotherapy the NT-proBNP three And the the think NT-proBNP a about tiny point that little data favorable, very things Griffon three are clinically New in I of NT-proBNP, of that their line about very question not data does They last weeks. score, You exciting burden XX is to patient to address the improvement want about Orenitram day, in to meaningful of the Medicine. don't out to not They color these improvements any class. get to is I'll don't at there the because not times just it's a So Uptravi, improve. was improved three we're want times don't did We just a have information These a whether Griffon you're Orenitram times it's way improvements XXX report board they we Griffon day right. trivial, meaningful, facilitated going intervals. have England patients

appearance, the analysis, never that post and indication analysis This an very into you benefit. suggested a the and FDA have week benefit of that's initial either in to talk a show important this we therapy can oral risk a can and a in at Orenitram that the talk take or clinically despite post to expensive survival of time, has ultimately an measured something drug stay create a study of the and drug translates ambition the you a XX which over was analysis drug So any seen finally, The that same with take concerned. very side-effect burden very was combination benefits similar not kind. pre-specified difference first

interesting reduction concerned and to saw we deaths in that We about balanced not randomized about see end mortality not those expect the be of treatment. a available on really in patients at If the study. assigned Orenitram for this. of excited letter do But patients the we a also And we're end deaths, in deaths it. had see expect you to you did about look XX% difference a website, very period to have the documents in the assigned as randomized concerned the were at Selexipag has They fact about that very the treatments. stock more of

effect clinically that it Uptravi. worse, slightly at get return patients a weeks. similar but benefits have XX meaningful is for profile in you And So side is to you

time. I that, get going difference clear to physicians. And have even You may that the think profile in to over survival and an risk you improved is improvement make very

Operator

Oppenheimer question Singh Our & Company. from from Hartaj comes next

line open. Your is now

Hartaj Singh

for FREEDOM-EV. you follow-up Thank question on the

Probably really ability you because Just or year said Dr. you year-and-half there I that Also approval. the question, imbalance deaths. Selexipag. an combine actually a in imbalance a as there - And the ago then mortality imbalance with following of dispensation improvement to post had the Liana's the France of stopped by Selexipag White increase think slight a titrated. plus getting had median was that a the does think that run decrease in on have and titration a physicians nice also How visit prescribing potential you hospitalization. impact show. you in on They long It's dose be in treprostinil flexibility the dose mortality you're oral thinking?

Martine Rothblatt

White would glad be Great, to Hartaj. Thanks Yes, the Dr. and for question. answer.

Jim White

except milligrams That's have daily [inaudible] earlier physicians associated and functional terms what a and quite dose which my Remodulin. a X class. won't dose benefits off right. presented response data dose I did So, is clinical that's of just terms more clear not apparent this of physician - clinical that to titration, are very times you again for titration say terms comfort in three it That's I And terms improvements a in indication tell NT-proBNP of on dose you are, patients dose and to doses plan terms of we aspect. of we become had talk in about is at do that. and I'll about that point benefits touched think the that improvements And detail pre-specified doses - in actually analyze and we sorry, hit on been comfortable we very I'm that in They're and right. comfortable with, in

ability and the don’t to daily a dose I three indication that right full the is Remodulin nurse of there have Orenitram. time think ability limitation, for dose daily to any we who the times dose that is have without move working titration we with of improvement is as times Orenitram. there or so that to time up three patient do milligrams continue further XX for that over the dose ceiling provide Orenitram, patients XX ceiling And a milligrams on to

support comfort Remodulin dose ability I that doesn’t coupled your increases Uptravi drug and that makes for infinitely large physicians think on So dose patient very for with insight have Remodulin this type that attractive.

of like data something to enduring stable that dose has improvements type survival an know produces they anything look an clinical package the starts indication improvement. that - and and terms Now meaningful clinical in benefit maybe drug for worsening has

James Edgemond

more Dr. looks White. question you it one there's Nicole like the thank Great, in queue.

So question. can next the you proceed to

Operator

Company. Cowen Our comes from [inaudible] from next and question

Your is open. line now

Unidentified Analyst

two Wanted And label the included expect the we to should be data see added label, portion that open components the yet? your may would benefits what in Thanks. have meetings expectations in to upcoming as observed of described about in that see, haven’t seen which been additional you what this the the filing to we that are data the well. will include

James Edgemond

Great, Chris address Dr. you White, question. thanks question. Chris' can the for

Jim White

what going question have. stay there heard we like going I'm going qualified that definitely away tell am I I I you I to piece. tell labeling to you what speculate that's will not to am I but in so answer I'll from labels, not that I'm - that far don't a that I about is on

open presented disease on the the you're at on data assessment this we’re see NT-proBNP difference. going functional being in in platform to ISHLT heard to - most but indications we You impacted asked on that year the on started risk scores is where the on board question the And next then the and very and and shifted exciting I ATS. open And am we and in risk label class over we results, is have survival, meeting presenting ATS effects a talk said the at then there walk label that's as risk also about And likely I data to the how impacted how exciting time. how how And at focus I the the accumulated. then Florida, data the have when to sort a about see see data. of In going to the very risk not meetings about have going of risk is the will presentation liberty we’re what primary from going bulk you're at upcoming meeting meeting that earlier, what upcoming meetings. be the to progression see the fully at impacted

James Edgemond

Dr. you queue. White. in no thank the questions more There's Great,

to Dr. back go follow-up seeing just do Mr. want I to on in in turn what terms market. the to the So earlier that of talked want over I question. about call what are Benkowitz Rothblatt we now to to

Michael Benkowitz

Dr. the on then regulatory address And Sure I question, didn’t thanks, last that to the James. just White guess to. touch question the component briefly wanted I of

December. in filed we application So, our label extension for

We engage makes as the what Dr. XX understand label the have most in not White FDA will has will reviewed that included if month it data discussions the this with FDA. the And that we so be all to with of morning. obviously time tell we

discussed the in to I about this with really engaging we think Dr. there some as data we So, around the with think is look discussions FDA supplement. label things those the interesting as provocative forward White really excited associated that we’re so data and

a this the the to in of terms limited I in in is degree will of only as market say of weeks. out three level what and been data, seeing even really we’re about In of a data uptake terms this market result for what

at announced at at PVRI presented and preserve this a publications. through gave our affairs wanted medical additional Dr. to information conferences we results the we from data ability either topline being White the at communicate conference medical January his So or August because conferences in until wasn't really presentation there these to August function

been has PVRI, at questions discuss physicians to in totality. data at think able its data have this physicians We're medical that presented around the functions data affairs look through set. are now our appropriately So to this able I that

marketing before year it, expect label there's renewed and latter And updated, put of we uptick. expect our year. that interest we part latter be the in at have see machine further be part can to to going this do the even of which we behind so sales we And Orenitram even this will then

come that just back and to we're kind in response the address of market want what I question seeing So around data. and to

I presented early natural give this weeks ago Barcelona. very, think the just data very it's way about three still in

Martine Rothblatt

myself And excitement has Hitting are the as presented right. in so the of that, the worsening to add of stuff patients unlocking about insert clinical press community right. to really do I everything was that, just going which in is that all And is the Right, endpoint the Mike, could the that with improvements, be the this clinical and of primary the not how well exciting in the excited knew dataset about release. to enables did. if nothing analysis physicians stuff and August

congratulating the commitment package had really of So line is and always this across finish see a treprostinil thank until opportunity can getting that this me the congratulating oral they about to reason feedback of anything line incredible data the reflecting from anybody that that about that finish ago. getting aspect great that oral personally there's analysis me physician say weeks program Martine are and with as treprostinil excited mine the the what I the on getting us already and never thought And for Orenitram a hoped for very senior peers physicians the they across investigator finally should had seen. and for to on I no data, have three as lead am the changed to

this worth long the to term. because Company value making is really of it the I to commitment team's my So think emphasizing speaks happen in the

James Edgemond

you you for joining all thank please morning. you Benkowitz We appreciate Michael insight White, so teleconference our study. really the Thank can conclude clinical perspective teleconference. FREEDOM-EV Dr. Nicole, much both And morning's your teleconference. who Great. this the join on and this

Operator

today's United by callers international replay with Thank you X-XXX-XXX-XXXX and using code X-XXX-XXX-XXXX, access will conference in rebroadcast week for available dialing XXXXXXX. Corporation for Therapeutics for be participating call. one A dialing

United Therapeutics (UTHR) 27 Feb 192018 Q4 Earnings call transcript